| Bioactivity | Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2]. |
| Invitro | Daratumumab（Anti-Human CD38）在表达 CD38 的淋巴瘤和 MM 衍生细胞系中诱导有效的 Ab 依赖性细胞毒性[2]。 0 --> Daratumumab (PBS) 相关抗体: |
| In Vivo | Daratumumab（腹腔注射；0.5 mg/kg；Daudi-luc 细胞攻击后 14 天）可抑制小鼠异种移植肿瘤模型中表达 CD38 的肿瘤细胞的生长[2]。 |
| Name | Daratumumab (PBS) |
| CAS | 945721-28-8 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23. [2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848. |